Vertex reports third quarter 2023 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the third quarter ended september 30, 2023, raised full year 2023 guidance for product revenue and reiterated full year 2023 guidance for operating expenses. “vertex has delivered another strong quarter across the business. we remain relentless in our commitment to reach more patients with our cystic fibrosis medicines, while preparing for the potential launch of exa-cel.
VRTX Ratings Summary
VRTX Quant Ranking